相关实验视频
Updated: Jun 24, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
BIN1和阿尔茨海默氏病:陶氏连接的关系
Pierre Dourlen1, Devrim Kilinc1, Isabelle Landrieu2
1Univ Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, Institut Pasteur de Lille, Université de Lille, Lille, France.
Trends in neurosciences
|April 23, 2025
概括
桥梁整合器1 (BIN1) 对大脑功能和阿尔茨海默病 (AD) 风险至关重要. 本综述强调了BIN1在突触调节中的作用,以及它与阿尔茨海默氏症中tau病理学的联系.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 细胞生物学 细胞生物学
背景情况:
- 桥梁整合体1 (BIN1) 是一种普遍表达的蛋白质,涉及细胞内,贩运和细胞骨动力学.
- 2010年,BIN1基因被确定为阿尔茨海默病 (AD) 的重要遗传风险因素.
- 此前,关于BIN1在大脑中的特定作用的数据有限.
研究的目的:
- 为了回顾BIN1在大脑中的多方面的作用.
- 探索BIN1与突触功能之间的联系.
- 为了检查BIN1和阿尔茨海默病的tau病理学之间的确定的联系.
主要方法:
- 文献综述综合遗传,临床,死后和分子数据.
- 对BIN1参与神经生物学相关的细胞过程的分析.
- BIN1遗传数据与AD风险和病理学的相关性.
主要成果:
- BIN1在突触功能调节中起着至关重要的作用.
- BIN1与阿尔茨海默氏症中tau病理学有着强烈的关联.
- 证据涵盖了遗传关联,临床观察,尸检研究和分子相互作用.
结论:
- BIN1是大脑功能的关键参与者,特别是突触调节.
- BIN1与阿尔茨海默病 (尤其是病理) 之间的联系是强有力的,并得到了各种证据的支持.
- 对BIN1的机制进行进一步的研究是有必要的,以了解AD的发病因子.
相关概念视频
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128

